All articles by Phillip Broadwith – Page 17
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
Mitsui continues reinvention efforts with two deals
Japanese firm drops organic acids in favour of lens materials
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business
Chinese police hand GSK bribery case to prosecutors
Investigation alleges senior manager ordered staff to hand out bribes
-
Business
Solvay-Ineos PVC deal passes European approval
Firms required to divest plants to maintain competition
-
Business
UK Lords urge government to take lead on fracking
Regulations holding back shale gas exploration, report says
-
Business
UK regulator warning over online herbal remedies
Products found to contain toxic metals or undeclared prescription-only drugs
-
Business
Insider trading allegations stall Sun–Ranbaxy deal
Companies deny wrongdoing in lead-up to merger announcement
-
Business
Forest Labs buys Furiex for bowel drug
Firm will immediately sell on other assets to Royalty Pharma
-
Business
BASF to cut 260 jobs in nutrition and health
Firm to sell Norwegian site and shift focus towards Asia
-
Feature
It's even cheaper being green
Reducing the environmental impact of your lab can save money as well as water and fuel. Phillip Broadwith reports
-
Business
Generics triumph in anti-inflammatory patent battle
Pfizer settles deals to allow copycat celecoxib
-
Business
GSK corruption investigation widens
BBC investigation airs allegations of misconduct in Poland
-
Business
Baxter aims to divide and conquer
Firm will split off its biopharmaceuticals business from medical products